| Today's Big NewsOct 26, 2022 |
|
A GPS to your next blockbuster drug - Design molecules towards your desired properties through AI+Biophysics. Learn more.
|
|
| By Nick Paul Taylor AstraZeneca has pulled off a pair of wins in breast cancer. After seeing rival drugs from Roche and Sanofi fail, the Anglo-Swedish drugmaker bucked the trend with wins for capivasertib and camizestrant in phase 2 and 3 clinical trials. |
|
|
|
By Heather Landi JPMorgan Chase is jumping into primary care and is piloting office-based clinics for employees in the Columbus, Ohio area. |
By Max Bayer Time BioVentures has closed its first $100 million fund, looking to find the next great biotech hit reminiscent of Silicon Valley success stories. Among the firm's early bets are Elon Musk's neurological medtech company Neuralink. |
By Conor Hale At a discussion on the post-pandemic future of diagnostics at AdvaMed’s Medtech Conference in Boston, industry leaders said there is still preparation to be done, and it may be needed sooner rather than later. |
By Fraiser Kansteiner Adding another layer of tech to its so-called EVolutive vaccine facilities in France and Singapore, Sanofi is tapping Dassault Systèmes’ simulated 3D spaces to optimize production through the power of the digital twin. |
By Zoey Becker In its latest effort to defend against forthcoming Entresto copycats, Novartis took to U.S. federal court to allege infringement against several generics players. |
By James Waldron Seres Therapeutics’ SER-109 has faced more setbacks than most therapies, but the biotech has kept the faith and now is tantalizingly close to possibly seeing its candidate become the first FDA-approved oral microbiome therapeutic. |
By Andrea Park In the nearly two years since the sales-sucking black hole that was 2020, Boston Scientific has dug itself out and then some. |
By Angus Liu After European regulators jumped on a global-first approval for Johnson & Johnson’s BCMA-targeted bispecific drug Tecvayli, the U.S. FDA has doled out its own blessing for the novel therapy. But the U.S. nod covers what appears to be a less favorable treatment setting. |
By Dave Muoio The acute and behavioral care company said its operations are still feeling the sting of COVID-19 and labor shortages. |
By Gabrielle Masson Recursion Pharmaceuticals has cut a rare disease asset from its pipeline while pulling in a $150 million private placement and nominating a new cancer program. |
By Fraiser Kansteiner Armed with three new launches in Opdualag, Camzyos and Sotyktu—plus its recent CAR-T entrants Breyanzi and Abecma—all four of BMS’ bread-and-butter therapeutic areas have reached “critical mass,” CEO Giovanni Caforio, M.D., said Wednesday. |
By Conor Hale Pacific Biosciences raised the curtain on two DNA sequencers, including its first short-read device—designed to offer new competition to the industry giant Illumina—as well as a machine poised to be an upgrade over its current long-read hardware. |
By Robert King Hospital groups are pressing lawmakers for more financial relief and passage of key telehealth and prior authorization reform bills in the upcoming lame duck Congress. |
Fierce podcastsDon't miss an episode |
| | This week on "Podnosis," we talk about how MA plans are rethinking their sales pitch. We also eavesdrop on a panel discussion at the Fierce Health Payer summit on how payers are looking to address social determinants of health. |
|
|---|
|
|
|
Tuesday, November 15, 2022 | 1pm ET / 10am PT In this webinar, learn how Medable is focused on improving access to clinical trials for patients, supporting the innovation of clinical trial delivery and offering greater choices for participation and engagement to patients. Register now.
|
|
| eBookImprove patient engagement, adherence, and outcomes Sponsored by: Health Catalyst |
| WhitepaperElectronic health records (EHR) and patient registries are both important sources of real-world evidence – but which is right for your needs? Sponsored by: Veradigm Health |
| eBookLooking to implement a remote patient monitoring (RPM) program at your organization? Download the eBook from Health Catalyst to learn the essential components of successful RPM programs. Sponsored by: Health Catalyst |
| eBookIn this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
| eBookWith real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
| Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT DATA |
| WhitepaperRead about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
| WhitepaperSaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
| WhitepaperThis paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
| Whitepaper Advanced research requires advanced tools. The next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Sponsored by: Bio-Techne |
| VideoCan an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
| VideoLearn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
| WhitepaperWhat is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
| ResearchLearn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| WebinarYpsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
| Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
| Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
| Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
| eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
| Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
| Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
